You are here

  • Home
  • Archive
  • Volume 8, Issue 3
  • Review: cardioselective β1 blockers given for 3 days to 4 weeks do not reduce respiratory function in reactive airway disease

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: cardioselective β1 blockers given for 3 days to 4 weeks do not reduce respiratory function in reactive airway disease

https://doi.org/10.1136/ebm.8.3.73

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2002) Ann Intern Med 137, 715; Salpeter SR, Ormiston TM, Salpeter EE.. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.. ;. :. –25.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTIONS: In patients with reactive airway disease, what is the effect of cardioselective β1 blockers on respiratory function? In these patients, how does treatment with β1 blockers affect response to β2 agonists?

    Data sources

    Studies were identified by searching Medline, EMBASE/Excerpta Medica, and CINAHL (all between 1966 and May 2001), and by scanning bibliographies of relevant studies and reviews.

    Study selection

    Studies in any language were selected if they were randomised, blinded, placebo controlled trials that assessed the effects of intravenous or oral cardioselective β1 blockers, given as a single dose or as continued treatment lasting ≥3 days, on airway function (FEV1 or symptoms) in patients with reactive airway disease (defined as asthma or chronic obstructive pulmonary disease with a reversible obstructive component).

    Data extraction

    Data were extracted on study quality, study design, patient characteristics, interventions, comparison groups, and outcomes (change in FEV1; FEV1 response to β2 …

    View Full Text

    Footnotes

    • Source of funding: no external funding.

    • For correspondence: Dr S Salpeter, Santa Clara Valley Medical Center, San Jose, California, USA. Shelley.salpeter{at}hhs.co.santa-clara.ca.us